GlassScriptPhysician profile
Robert M Koffie
NPI 1760744460
$13,180.74
in general payments reported to CMS, 2019-2025
12 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $685 · 2021: $712 · 2022: $8,527 · 2023: $576 · 2024: $1,722 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,753 · Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,753.00 |
| Food and Beverage | $1,333.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $8,033.18 | 2022 | |
| Nuvasive, INC. | $2,233.97 | 2019-2023 | Alif, Acp, Xlif |
| Globus Medical, INC. | $928.64 | 2024-2025 | Elsa, Reline, Altera |
| Impactortho, INC. | $760.37 | 2024 | |
| Arthrex, INC. | $521.30 | 2024 | |
| Medtronic, INC. | $273.14 | 2021-2022 | |
| Abbott Laboratories | $206.66 | 2024 | Proclaim |
| Nevro Corp. | $93.21 | 2024 | Senza |
| Si-Bone, INC. | $46.31 | 2022 | |
| Depuy Synthes Sales INC. | $42.00 | 2022-2023 | Expedium, Viper, Expedium Verse |
| Medtronic USA, INC. | $27.47 | 2020 | |
| Seqirus USA INC | $14.49 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Koffie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.